GLAS
Price
$6.80
Change
-$0.35 (-4.90%)
Updated
Sep 25 closing price
Capitalization
639.91M
52 days until earnings call
Intraday BUY SELL Signals
TLRY
Price
$4.13
Change
+$0.06 (+1.47%)
Updated
Sep 25 closing price
Capitalization
579.95M
Intraday BUY SELL Signals
Interact to see
Advertisement

GLAS vs TLRY

GLAS vs TLRY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GLAS vs. TLRY commentary
Sep 27, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLAS is a Hold and TLRY is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
GLAS vs TLRY: Fundamental Ratings
GLAS
TLRY
OUTLOOK RATING
1..100
5550
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
38
Fair valued
PROFIT vs RISK RATING
1..100
80100
SMR RATING
1..100
9892
PRICE GROWTH RATING
1..100
8782
P/E GROWTH RATING
1..100
10091
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLRY's Valuation (38) in the Biotechnology industry is in the same range as GLAS (44) in the null industry. This means that TLRY’s stock grew similarly to GLAS’s over the last 12 months.

GLAS's Profit vs Risk Rating (80) in the null industry is in the same range as TLRY (100) in the Biotechnology industry. This means that GLAS’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's SMR Rating (92) in the Biotechnology industry is in the same range as GLAS (98) in the null industry. This means that TLRY’s stock grew similarly to GLAS’s over the last 12 months.

TLRY's Price Growth Rating (82) in the Biotechnology industry is in the same range as GLAS (87) in the null industry. This means that TLRY’s stock grew similarly to GLAS’s over the last 12 months.

TLRY's P/E Growth Rating (91) in the Biotechnology industry is in the same range as GLAS (100) in the null industry. This means that TLRY’s stock grew similarly to GLAS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLASTLRY
RSI
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 24 days ago
82%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
85%
COMPARISON
Comparison
Sep 27, 2026
Stock price -- (GLAS: $6.80 vs. TLRY: $4.13)
Brand notoriety: GLAS: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: GLAS: 311% vs. TLRY: 49%
Market capitalization -- GLAS: $639.91M vs. TLRY: $579.95M
GLAS [@Pharmaceuticals: Generic] is valued at $639.91M. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $579.95M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $66.76B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLAS’s FA Score shows that 0 FA rating(s) are green while TLRY’s FA Score has 0 green FA rating(s).

  • GLAS’s FA Score: 0 green, 5 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, both GLAS and TLRY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLAS’s TA Score shows that 4 TA indicator(s) are bullish while TLRY’s TA Score has 6 bullish TA indicator(s).

  • GLAS’s TA Score: 4 bullish, 5 bearish.
  • TLRY’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, TLRY is a better buy in the short-term than GLAS.

Price Growth

GLAS (@Pharmaceuticals: Generic) experienced а -14.68% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was +3.51% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.49%. For the same industry, the average monthly price growth was -6.14%, and the average quarterly price growth was +42.31%.

Reported Earning Dates

GLAS is expected to report earnings on Nov 18, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+3.49% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
GLAS
Daily Signal:
Gain/Loss:
TLRY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
APG38.460.63
+1.67%
APi Group Corporation
ICON0.99-0.01
-1.00%
Icon Energy Corp.
ALLO1.65-0.02
-1.20%
Allogene Therapeutics
BRZE24.37-0.30
-1.22%
Braze
EP2.11-0.15
-6.64%
Empire Petroleum Corp

GLAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLAS has been closely correlated with TRLV. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLAS jumps, then TRLV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLAS
1D Price
Change %
GLAS100%
-4.90%
TRLV - GLAS
71%
Closely correlated
-0.49%
CGC - GLAS
63%
Loosely correlated
+1.35%
TLRY - GLAS
59%
Loosely correlated
+1.47%
YCBD - GLAS
53%
Loosely correlated
+1.96%
CRON - GLAS
52%
Loosely correlated
+0.60%
More